The American Academy of Pediatrics (AAP) has drawn criticism for endorsing the idea that children can consent to experimental “transgender” medical treatments, despite acknowledging the need for more research. The AAP supports “gender-affirming care,” which includes interventions such as puberty blockers and cross-sex hormones. Many European countries have taken a more cautious approach, adopting a “watchful waiting” stance and withdrawing support for childhood gender interventions.
There is a lack of concrete evidence to support the efficacy and safety of these treatments. The use of puberty blockers and cross-sex hormones can lead to hormone imbalances and potential long-term risks such as infertility, low bone density, and increased susceptibility to diseases.
Doctors and experts have testified against funding gender-affirming care through Medicaid, highlighting the lack of reliable and valid research studies on the effectiveness and safety of these interventions. They argue that the current standards of care supporting these treatments are more driven by political and advocacy efforts rather than objective analysis.
The AAP’s decision to launch a systematic review of the evidence is a step in the right direction. The number of detransitioners stepping forward to tell their horror stories is evidence enough that this process is not only morally corrupt, but is also incredibly devastating to the physical and mental health of children.